Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
EGFR
drug resistance
target therapy
Journal
Biochemical Society transactions
ISSN: 1470-8752
Titre abrégé: Biochem Soc Trans
Pays: England
ID NLM: 7506897
Informations de publication
Date de publication:
29 04 2020
29 04 2020
Historique:
received:
04
02
2020
revised:
26
03
2020
accepted:
30
03
2020
pubmed:
21
4
2020
medline:
20
2
2021
entrez:
21
4
2020
Statut:
ppublish
Résumé
Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-positive breast cancer patients, and is considered as a keystone of systemic cancer therapy. Likewise, HER2-targeted therapy significantly improved the survival of HER2-positive breast cancer patients, indicating that targeted therapy is a powerful therapeutic strategy for breast cancer. However, for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, there are no clinically approved targeted therapies, and thus, an urgent need to identify potent, highly effective therapeutic targets. In this mini-review, we describe general strategies to inhibit tumor growth by targeted therapies and briefly discuss emerging resistance mechanisms. Particularly, we focus on therapeutic targets for TNBC and discuss combination therapies targeting the epidermal growth factor receptor (EGFR) and associated resistance mechanisms.
Identifiants
pubmed: 32311020
pii: 222712
doi: 10.1042/BST20191055
doi:
Substances chimiques
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-665Informations de copyright
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.